Eptifibatide

Trade names

INTEGRILIN

Actions

• Reversible glycoprotein IIb/IIIa inhibitor.

Route of Administration

Intravenous

Bioavailability

100%

Plasma protein binding

~25%

Time to peak plasma concentration

Dose dependent

Time to plasma steady state

Dose dependent, rapid after bolus.

Half-life

2.5 h

Elimination

Renal up to 50%.

Duration of action

2–4 h

Reversible platelet inhibition

Yes

Recommended dose

Bolus dose 180 μg/kg, followed by continuous maintenance infusion of 2 μg/kg/min for up to 72 hours.

Indicated in acute coronary syndrome and percutaneous coronary intervention (PCI)

Renal impairment

In patients with creatinine clearance ≥30 - <50 ml/min the maintenance dose should be reduced to 1 μg/kg/min.

Eptifibatide is contraindicated in patients with creatinine clearance <30 ml/min.

Discontinuation before invasive procedures

8 h